172
Views
4
CrossRef citations to date
0
Altmetric
Review

A Deep Dive into the Pathology of Gray Platelet Syndrome: New Insights on Immune Dysregulation

, & ORCID Icon
Pages 719-732 | Published online: 11 Aug 2021

References

  • Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21(1):21–36. doi:10.1016/j.blre.2005.12.003
  • Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med. 1971;51(6):818–828.
  • Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood. 2010;116(23):4990–5001.
  • Fabbro S, Kahr WH, Hinckley J, et al. Homozygosity mapping with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the interval significantly. Blood. 2011;117(12):3430–3434.
  • Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738–740.
  • Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735–737.
  • Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet. 2011;43(8):732–734.
  • Sims MC, Mayer L, Collins JH, et al. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood. 2020;136(17):1956–1967.
  • Cullinane AR, Schäffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic. 2013;14(7):749–766.
  • Bottega R, Pecci A, De Candia E, et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and -granule deficiency. Haematologica. 2013;98(6):868–874. doi:10.3324/haematol.2012.075861
  • Rensing-Ehl A, Pannicke U, Zimmermann SY, et al. Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome. Blood. 2015;126(16):1967–1969.
  • Wijgaerts A, Wittevrongel C, Thys C, et al. The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer. Haematologica. 2017;102(4):695–706.
  • Bottega R, Nicchia E, Alfano C, et al. Gray platelet syndrome: novel mutations of the NBEAL2 gene. Am J Hematol. 2017;92(2):E20–E22.
  • Cao L, Su J, Jiaming J, et al. A novel nonsense NBEAL2 gene mutation causing severe bleeding in a patient with gray platelet syndrome. Platelets. 2018;29(3):288–291.
  • Steinberg-Shemer O, Tamary H. Gray platelet syndrome mimicking atypical autoimmune lymphoproliferative syndrome: the key is in the blood smear. Blood. 2018;131(24):2737.
  • Pluthero FG, Di Paola J, Carcao MD, Kahr WHA. NBEAL2 mutations and bleeding in patients with gray platelet syndrome. Platelets. 2018;29(6):632–635.
  • Saliba AN, Ferrer A, Gangat N, et al. Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: a single institutional study of four patients. Br J Haematol. 2020;190(5):e316–e320.
  • Aarts CEM, Downes K, Hoogendijk AJ, et al. Neutrophil specific granule and NETosis defects in gray platelet syndrome. Blood Adv. 2021;5(2):549–564.
  • Tariq H, Perez Botero J, Higgins RA, Medina EA. Gray Platelet Syndrome presenting with pancytopenia, splenomegaly, and bone marrow fibrosis. Am J Clin Pathol. 2021;aqaa229. doi:10.1093/ajcp/aqaa229.
  • Ross JE, Zhang BM, Lee K, et al. Specifications of the variant curation guidelines for ITGA2B/ITGB3: clinGen Platelet Disorder Variant Curation Panel. Blood Adv. 2021;5(2):414–431.
  • White JG. Ultrastructural studies of the gray platelet syndrome. Am J Pathol. 1979;95(2):445–462.
  • De Candia E, Pecci A, Ciabattoni G, et al. Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives. J Thromb Haemost. 2007;5(3):551–559.
  • Glembotsky AC, Marta RF, Pecci A, et al. International collaboration as a tool for diagnosis of patients with inherited thrombocytopenia in the setting of a developing country. J Thromb Haemost. 2012;10(8):1653–1661.
  • Cramer EM, Vainchenker W, Vinci G, Guichard J, Breton-Gorius J. Gray platelet syndrome: immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes. Blood. 1985;66(6):1309–1316.
  • Drouin A, Favier R, Massé JM, et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood. 2001;98(5):1382–1391.
  • Rosa JP, George JN, Bainton DF, Nurden AT, Caen JP, McEver RP. Gray platelet syndrome: demonstration of a-granule membranes that can fuse with the cell surface. J Clin Invest. 1987;80:1138–1146.
  • Pluthero FG, Kahr WHA. Gray platelet syndrome: NBEAL2 mutations are associated with pathology beyond megakaryocyte and platelet function defects. J Thromb Haemost. 2021;19(2):318–322.
  • Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol. 1981;102(1):10–19.
  • Chen CH, Lo RW, Urban D, Pluthero FG, Kahr WH. α-granule biogenesis: from disease to discovery. Platelets. 2017;28(2):147–154.
  • Kahr WH, Lo RW, Li L, et al. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood. 2013;122(19):3349–3358.
  • Guerrero JA, Bennett C. van der Weyden L et al. Gray platelet syndrome: proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood. 2014;124(24):3624–3635.
  • Deppermann C, Cherpokova D, Nurden P, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest. 2013;123(8):3331–3342.
  • Lo RW, Li L, Leung R, Pluthero FG, Kahr W. NBEAL2 (Neurobeachin-Like 2) is required for retention of cargo proteins by α-granules during their production by megakaryocytes. Arterioscler Thromb Vasc Biol. 2018;38(10):2435–2447.
  • Mayer L, Jasztal M, Pardo M, et al. The BEACH-domain containing protein, Nbeal2, interacts with Dock7, Sec16a and Vac14. Blood. 2018;131:1000–1011.
  • Sviderskaya EV, Novak EK, Swank RT, Bennett DC. The murine misty mutation: phenotypic effects on melanocytes, platelets and brown fat. Genetics. 1998;148(1):381–390.
  • Lo RW, Li L, Pluthero FG, Leung R, Eto K, Kahr WHA. The endoplasmic reticulum protein SEC22B interacts with NBEAL2 and is required for megakaryocyte α-granule biogenesis. Blood. 2020;136(6):715–725.
  • Nurden AT, Nurden P. Should any genetic defect affecting α-granules in platelets be classified as gray platelet syndrome? Am J Hematol. 2016;91(7):714–718.
  • Noris P, Biino G, Pecci A, et al. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. Blood. 2014;124(6):e4–e10.
  • Larocca LM, Heller PG, Podda G, et al. Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome. Platelets. 2015;26(8):751–757.
  • Nurden P, Jandrot-Perrus M, Combrié R, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood. 2004;104(1):107–114.
  • Di Buduo CA, Alberelli MA, Glembotsky AC, et al. Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients. Sci Rep. 2016;6:25027.
  • Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363.
  • Chedani H, Dupuy E, Massé JM, Cramer EM. Neutrophil secretory defect in the gray platelet syndrome: a new case. Platelets. 2006;17(1):14–19.
  • White JG, Brunning RD. Neutrophils in the gray platelet syndrome. Platelets. 2004;15(5):333–340.
  • Zittoun J, Zittoun R, Marquet J, Sultan C. The three transcobalamins in myeloproliferative disorders and acute leukemia. Br J Haematol. 1975;31(3):287–298.
  • Kahr WH, Dror Y. Gray platelet syndrome: macrothrombocytopenia with deficient α-granules. Blood. 2012;120(13):2543.
  • Sowerby JM, Thomas DC, Clare S, et al. NBEAL2 is required for neutrophil and NK cell function and pathogen defense. J Clin Invest. 2017;127(9):3521–3526.
  • Claushuis TAM, de Stoppelaar SF, de Vos AF, et al. Nbeal2 Deficiency Increases Organ Damage but Does Not Affect Host Defense During Gram-Negative Pneumonia-Derived Sepsis. Arterioscler Thromb Vasc Biol. 2018;38(8):1772–1784.
  • Drube S, Grimlowski R, Deppermann C, et al. The Neurobeachin-like 2 Protein Regulates Mast Cell Homeostasis. J Immunol. 2017;199(8):2948–2957.
  • Rip J, Van Der Ploeg EK, Hendriks RW, Corneth OBJ. The role of Bruton’s Tyrosine Kinase in immune cell signaling and systemic autoimmunity. Crit Rev Immunol. 2018;38(1):17–62.
  • Zaninetti C, Gresele P, Bertomoro A, et al. Eltrombopag for the treatment of inherited thrombocytopenias: a Phase II clinical trial. Haematologica. 2020;105(3):820–828.
  • Favier R, Roussel X, Audia S, et al. Correction of severe myelofibrosis, impaired platelet functions and abnormalities in a patient with Gray Platelet Syndrome successfully treated by stem cell transplantation. Platelets. 2020;31(4):536–540.